AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

enabling them to probe molecular phenotypes directly relevant to the development of drugs that target this receptor. In this important work, the authors provide compelling evidence that variants ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

Researchers may have stumbled upon the secret to anti-aging medication in a pill that's already widely used and readily ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...